Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

Who can take part

Inclusion Criteria: To be included in the trial, subjects must meet all of the following criteria: 1. Provision of written informed consent prior to participation. 2. Age ≥18 years. 3. Scheduled for first-time catheter ablation for atrial fibrillation using a pulmonary vein isolation (PVI) technique. 4. Body Mass Index (BMI) ≥30 kg/m² (obesity) OR BMI ≥27 kg/m² (overweight) with one or more of the following comorbidities: * prediabetes (defined as HbA1c 39-47 mmol/mol or fasting glucose 5,6-6,9 mmol/L), * known diabetes type 2 * known hypertension (prior diagnosis and/or treatment with antihypertensive medication) * new diagnosis of hypertension (according to ESC GL for hypertension: Systolic BP ≥140 mmHg and/or diastolic BP ≥ 90 mmHg based on two readings on two separate visits, OR Ambulatory BP monitoring (24h average) ≥ 130/80 mmHg) * dyslipidemia defined as either one of the following * Known diagnosis of hyperlipidemia or * Treatment with lipid lowering medication OR either of the following: * LDL \> 3.0 mmol/l * Total cholesterol \> 5 mmol/l * Triglycerides \> 1.7 mmol/l * HDL (\< 1 mmol/l if male, \< 1.2 mmol/l if female) AND/OR * atherosclerotic cardiovascular disease (prior myocardial infarction (MI), stroke, or peripheral arterial disease with claudication and ankle-brachial index \<0.85, prior revascularization, or amputation) * obstructive sleep apnea. 5. For women of childbearing potential: Inclusion after a highly sensitive negative pregnancy test and agreement to use highly effective contraception during the study period (e.g., hormonal contraception, intrauterine device, or barrier method combined with spermicide). Exclusion Criteria: * Morbid obesity (BMI \>40 kg/m²). * Current use of GLP-1 receptor agonist therapy or dual agonist therapy within 6 months before screening. * Current use of DPP-IV inhibitors. * Diabetes type 1 * Known intolerance or contraindication to semaglutide. * History of pancreatitis or recurrent hypoglycemia. * Uncontrolled diabetic retinopathy * Severe renal failure (estimated glomerular filtration rate \[eGFR\] \<15 mL/min/1.73 m² or in dialysis) * Severe hepatic failure (decompensated liver disease Child-Pugh class C) * Severe cardiac failure (NYHA class IV) * Life expectancy \<12 months. * Inability to self-administer the investigational medicinal product. * Prior catheter ablation procedure for atrial fibrillation. * Pregnancy, breastfeeding, or planned pregnancy during or within two months after the study period. * Participation in another interventional clinical trial within the past 30 days.

Registry changes

No changes recorded since the trial was added.